Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:7/13/2016
Start Date:August 2015
Contact:Kristen Quigley
Email:kquigley@thresholdpharm.com

Use our guide to learn which trials are right for you!

A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

This phase 2 study is designed to evaluate the safety and activity of TH-4000, a
hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell
carcinoma of the head and neck or skin.

An open label, parallel-group, multi-center Phase 2 study in which the pharmacokinetics,
safety, tolerability and efficacy of TH-4000 will be assessed in participants with recurrent
or metastatic squamous cell carcinoma of the head and neck or skin.

Hypoxia PET scans will be obtained in select centers to analyze potential predictors of
tumor response.

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Confirmed squamous cell carcinoma of the head and neck (oropharynx, oral cavity,
hypopharynx, or larynx) or skin

- For patients with oropharyngeal cancer, p16 status is known or can be determined

- Measurable disease according to Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST 1.1)

- Acceptable laboratory results as indicated by protocol

- Acceptable cardiac function as indicated by protocol

Exclusion Criteria:

- Received prior EGFR TKI therapy for recurrent or metastatic SCC (e.g., oral EGFR TKIs
such as erlotinib, gefitinib, or afatinib)

- Family history of long QTc syndrome

- Receiving medication that prolongs QT interval ,with a risk of causing Torsades de
Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the
medication

- Family history of long QTc syndrome

- Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy

- Radiation therapy within 2 weeks prior to the first dose of study medication

- Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose
of study medication

- Concurrent active malignancy requiring systemic treatment

- Any other serious uncontrolled medical disorders or psychological conditions that may
interfere with study conduct including but not limited to: clinically significant
active infection

- Pregnant or breast-feeding
We found this trial at
9
sites
Stanford, California 94305
Principal Investigator: Alexandar D Colevas
?
mi
from
Stanford, CA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Camperdown, New South Wales 2050
?
mi
from
Camperdown,
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Los Angeles, California 90033
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Nashville, Tennessee 37232
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials